Springer eBooks, Год журнала: 2024, Номер unknown, С. 485 - 520
Опубликована: Янв. 1, 2024
Язык: Английский
Ageing Research Reviews, Год журнала: 2025, Номер unknown, С. 102670 - 102670
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Pharmacological Research, Год журнала: 2025, Номер unknown, С. 107723 - 107723
Опубликована: Апрель 1, 2025
Because of the deregulation protein kinase action in many inflammatory diseases and cancer, family has become one most significant drug targets 21st century. There are 85 FDA-approved antagonists that target about two dozen different enzymes four these drugs were approved 2024 a fifth was 2025. Of drugs, five dual specificity kinases (MEK1/2), fourteen inhibit protein-serine/threonine kinases, twenty-one block nonreceptor protein-tyrosine 45 receptor kinases. The data indicate 75 prescribed for treatment neoplasms. Seven (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) management (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, ulcerative colitis). agents, used multiple diseases. following received FDA approval - deuruxolitinib (alopecia areata), ensartinib lazertinib (non-small cell lung cancer), tovorafenib (pediatric glioma) while mirdametinib 2025 type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, trilaciclib, blockers orally bioavailable. This article summarizes physicochemical properties all small molecule inhibitors including molecular weight, number hydrogen bond donors/acceptors, ligand efficiency, lipophilic polar surface area, solubility. A total 39 have least Lipinski rule 5 violation.
Язык: Английский
Процитировано
0
Springer eBooks, Год журнала: 2024, Номер unknown, С. 485 - 520
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0